| 0 (0%) | 09-27 09:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.56 | 1-year : | 9.99 |
| Resists | First : | 7.32 | Second : | 8.56 |
| Pivot price | 6.35 |
|||
| Supports | First : | 6.31 | Second : | 5.67 |
| MAs | MA(5) : | 6.4 |
MA(20) : | 6.34 |
| MA(100) : | 8.5  |
MA(250) : | 12.38 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 58.5 |
D(3) : | 48.8 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 23.39 | Low : | 5.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CAPR ] has closed It is unclear right now based on current values. 78.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.28 - 7.31 | 7.31 - 7.33 |
| Low: | 6.28 - 6.31 | 6.31 - 6.34 |
| Close: | 7.04 - 7.08 | 7.08 - 7.12 |
Fri, 26 Sep 2025
Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains? - Yahoo Finance
Thu, 25 Sep 2025
CAPR Stock: Analyst Reiterates Buy Rating with $24 Price Target - GuruFocus
Thu, 25 Sep 2025
Capricor Therapeutics (CAPR) Gains on FDA Regulatory Flexibility for Deramiocel - GuruFocus
Thu, 25 Sep 2025
Capricor gains as FDA mulls ‘regulatory flexibility’ for lead asset - Seeking Alpha
Thu, 25 Sep 2025
Capricor climbs as FDA clears path for resubmission of cell therapy application - TradingView
Thu, 25 Sep 2025
Capricor Therapeutics Announces FDA Alignment on HOPE-3 Trial Endpoints for Deramiocel BLA Resubmission - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 46 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 16.7 (%) |
| Held by Institutions | 30.5 (%) |
| Shares Short | 11,490 (K) |
| Shares Short P.Month | 11,110 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.29 |
| Profit Margin | 0 % |
| Operating Margin | -548.2 % |
| Return on Assets (ttm) | -53.5 % |
| Return on Equity (ttm) | -120.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.18 |
| Sales Per Share | 0.29 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -4.46 |
| PEG Ratio | 0 |
| Price to Book value | 3.08 |
| Price to Sales | 24.2 |
| Price to Cash Flow | -6.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|